466 related articles for article (PubMed ID: 24501221)
61. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.
Zenz T; Kröber A; Scherer K; Häbe S; Bühler A; Benner A; Denzel T; Winkler D; Edelmann J; Schwänen C; Döhner H; Stilgenbauer S
Blood; 2008 Oct; 112(8):3322-9. PubMed ID: 18689542
[TBL] [Abstract][Full Text] [Related]
62. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.
Griffin R; Wiedmeier-Nutor JE; Parikh SA; McCabe CE; O'Brien DR; Boddicker NJ; Kleinstern G; Rabe KG; Bruins L; Brown S; Bonolo de Campos C; Ding W; Leis JF; Hampel PJ; Call TG; Van Dyke DL; Kay NE; Cerhan JR; Yan H; Slager SL; Braggio E
Blood Adv; 2023 Jul; 7(13):3169-3179. PubMed ID: 36877634
[TBL] [Abstract][Full Text] [Related]
63. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.
Messina M; Del Giudice I; Khiabanian H; Rossi D; Chiaretti S; Rasi S; Spina V; Holmes AB; Marinelli M; Fabbri G; Piciocchi A; Mauro FR; Guarini A; Gaidano G; Dalla-Favera R; Pasqualucci L; Rabadan R; Foà R
Blood; 2014 Apr; 123(15):2378-88. PubMed ID: 24550227
[TBL] [Abstract][Full Text] [Related]
64. The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.
Wang C; Wang X
Int J Clin Exp Pathol; 2013; 6(7):1223-9. PubMed ID: 23826404
[TBL] [Abstract][Full Text] [Related]
65. Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
Guarini A; Peragine N; Messina M; Marinelli M; Ilari C; Cafforio L; Raponi S; Bonina S; Mariglia P; Mauro FR; Gaidano G; Del Giudice I; Foà R
Br J Haematol; 2019 Feb; 184(3):392-396. PubMed ID: 30338509
[TBL] [Abstract][Full Text] [Related]
66. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
Kojima K; Duvvuri S; Ruvolo V; Samaniego F; Younes A; Andreeff M
Cancer; 2012 Feb; 118(4):1023-31. PubMed ID: 21761401
[TBL] [Abstract][Full Text] [Related]
67. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome.
Brieghel C; da Cunha-Bang C; Yde CW; Schmidt AY; Kinalis S; Nadeu F; Andersen MA; Jacobsen LO; Andersen MK; Pedersen LB; Delgado J; Baumann T; Mattsson M; Mansouri L; Rosenquist R; Campo E; Nielsen FC; Niemann CU
Clin Cancer Res; 2020 Mar; 26(6):1507-1515. PubMed ID: 31919133
[TBL] [Abstract][Full Text] [Related]
68. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.
Malcikova J; Smardova J; Rocnova L; Tichy B; Kuglik P; Vranova V; Cejkova S; Svitakova M; Skuhrova Francova H; Brychtova Y; Doubek M; Brejcha M; Klabusay M; Mayer J; Pospisilova S; Trbusek M
Blood; 2009 Dec; 114(26):5307-14. PubMed ID: 19850740
[TBL] [Abstract][Full Text] [Related]
69. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
Sutton LA; Ljungström V; Mansouri L; Young E; Cortese D; Navrkalova V; Malcikova J; Muggen AF; Trbusek M; Panagiotidis P; Davi F; Belessi C; Langerak AW; Ghia P; Pospisilova S; Stamatopoulos K; Rosenquist R
Haematologica; 2015 Mar; 100(3):370-6. PubMed ID: 25480502
[TBL] [Abstract][Full Text] [Related]
70. Tumor Protein 53 Gene Mutations Without 17p13 Deletion Have No Significant Clinical Implications in Chronic Lymphocytic Leukemia. Detection of a New Mutation.
Diamantopoulos PT; Samara S; Kollia P; Giannakopoulou N; Sofotasiou M; Kalala F; Kodandreopoulou E; Zervakis P; Vassilakopoulos T; Siakantaris M; Mantzourani M; Angelopoulou M; Kyrtshonis MC; Korkolopoulou P; Patsouris E; Viniou NA
Anticancer Res; 2017 May; 37(5):2387-2391. PubMed ID: 28476805
[TBL] [Abstract][Full Text] [Related]
71. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia.
Stamatopoulos B; Timbs A; Bruce D; Smith T; Clifford R; Robbe P; Burns A; Vavoulis DV; Lopez L; Antoniou P; Mason J; Dreau H; Schuh A
Leukemia; 2017 Apr; 31(4):837-845. PubMed ID: 27795555
[TBL] [Abstract][Full Text] [Related]
72. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
Young E; Noerenberg D; Mansouri L; Ljungström V; Frick M; Sutton LA; Blakemore SJ; Galan-Sousa J; Plevova K; Baliakas P; Rossi D; Clifford R; Roos-Weil D; Navrkalova V; Dörken B; Schmitt CA; Smedby KE; Juliusson G; Giacopelli B; Blachly JS; Belessi C; Panagiotidis P; Chiorazzi N; Davi F; Langerak AW; Oscier D; Schuh A; Gaidano G; Ghia P; Xu W; Fan L; Bernard OA; Nguyen-Khac F; Rassenti L; Li J; Kipps TJ; Stamatopoulos K; Pospisilova S; Zenz T; Oakes CC; Strefford JC; Rosenquist R; Damm F
Leukemia; 2017 Jul; 31(7):1547-1554. PubMed ID: 27890934
[TBL] [Abstract][Full Text] [Related]
73. LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations.
Kristensen L; Kristensen T; Abildgaard N; Royo C; Frederiksen M; Mourits-Andersen T; Campo E; Møller MB
Eur J Haematol; 2016 Aug; 97(2):175-82. PubMed ID: 26558352
[TBL] [Abstract][Full Text] [Related]
74. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
[TBL] [Abstract][Full Text] [Related]
75. Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.
Baer C; Dicker F; Kern W; Haferlach T; Haferlach C
Leukemia; 2017 Jun; 31(6):1355-1362. PubMed ID: 27840426
[TBL] [Abstract][Full Text] [Related]
76. Single-Cell Analysis and Next-Generation Immuno-Sequencing Show That Multiple Clones Persist in Patients with Chronic Lymphocytic Leukemia.
Kriangkum J; Motz SN; Mack T; Beiggi S; Baigorri E; Kuppusamy H; Belch AR; Johnston JB; Pilarski LM
PLoS One; 2015; 10(9):e0137232. PubMed ID: 26353109
[TBL] [Abstract][Full Text] [Related]
77. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
78. Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia.
Hurtado AM; Chen-Liang TH; Przychodzen B; Hamedi C; Muñoz-Ballester J; Dienes B; García-Malo MD; Antón AI; de Arriba F; Teruel-Montoya R; Ortuño FJ; Vicente V; Maciejewski JP; Jerez A
Blood Cancer J; 2015 Aug; 5(8):e342. PubMed ID: 26314984
[TBL] [Abstract][Full Text] [Related]
79. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.
Barrio S; Shanafelt TD; Ojha J; Chaffee KG; Secreto C; Kortüm KM; Pathangey S; Van-Dyke DL; Slager SL; Fonseca R; Kay NE; Braggio E
Leukemia; 2017 Jan; 31(1):170-176. PubMed ID: 27469216
[TBL] [Abstract][Full Text] [Related]
80. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.
Rossi D; Rasi S; Spina V; Bruscaggin A; Monti S; Ciardullo C; Deambrogi C; Khiabanian H; Serra R; Bertoni F; Forconi F; Laurenti L; Marasca R; Dal-Bo M; Rossi FM; Bulian P; Nomdedeu J; Del Poeta G; Gattei V; Pasqualucci L; Rabadan R; Foà R; Dalla-Favera R; Gaidano G
Blood; 2013 Feb; 121(8):1403-12. PubMed ID: 23243274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
